Operating Cash Flow Turns Positive for the First Time, with a Significantly Strengthened Capital Structure
On August 28, 2026, Micot Pharma (02335.HK), the first publicly...
- 'Repairing the Roof on a Sunny Day' Efforts Pay Off as Innovation + Globalization Accelerate Growth
On the evening of 27 August, Fosun International...
CanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately RMB 550 million,...
Everest Medicines (HKG: 01952) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important...
On August 16, 2026, CanSino Biologics Inc. ("CanSinoBIO"; HKEX: 06185/SHSE: 688185) announced that the New Drug Application (NDA) for its Tetanus, Reduced Diphtheria and...
HONG KONG, August 7, 2026 - (ACN Newswire) - On August 3, 2026, Shaanxi Micot Pharmaceutical Technology Co., Ltd. ("Micot Pharma"; 2335.HK) announced positive topline...
